Publications by authors named "J B Ntakpe"
Article Synopsis
- People with HIV (PWH) treated for tuberculosis (TB) may develop a condition called TB-associated immune reconstitution inflammatory syndrome (TB-IRIS) after starting antiretroviral therapy (ART), which includes integrase inhibitors like raltegravir and non-nucleoside reverse transcriptase inhibitors like efavirenz.
- A study analyzed data from the Reflate TB 2 trial, which compared the occurrence of TB-IRIS in PWH receiving either raltegravir or efavirenz-based ART while undergoing standard TB treatment.
- The results showed that the incidence of TB-IRIS was similar in both ART groups, with 48 participants developing TB-IRIS, and identified risk factors such as low CD4
Increasing the uptake of Intermittent Preventive Treatment of malaria in pregnancy using Sulfadoxine-Pyrimethamine (IPTp-SP) through seasonal malaria chemoprevention channel delivery: protocol of a multicenter cluster randomized implementation trial in Mali and Burkina Faso.
BMC Public Health
January 2024
Background: The uptake of Intermittent Preventive Treatment of malaria in pregnancy using Sulfadoxine-Pyrimethamine (IPTp-SP) remains unacceptably low, with more than two-thirds of pregnant women in sub-Saharan Africa still not accessing the three or more doses recommended by the World Health Organisation (WHO). In contrast, the coverage of Seasonal Malaria Chemoprevention (SMC), a more recent strategy recommended by the WHO for malaria prevention in children under five years living in Sahelian countries with seasonal transmission, including Mali and Burkina-Faso, is high (up to 90%). We hypothesized that IPTp-SP delivery to pregnant women through SMC alongside antenatal care (ANC) will increase IPTp-SP coverage, boost ANC attendance, and increase public health impact.
View Article and Find Full Text PDFArticle Synopsis
- In the Reflate TB2 trial, researchers studied factors linked to virologic success and adherence in people with HIV and tuberculosis receiving raltegravir or efavirenz treatment.
- Out of 444 participants, 65% achieved virologic success (HIV-1 RNA <50 copies/mL) and maintained adherence (≥95% pill count) over 48 weeks, with several factors influencing these outcomes.
- Key findings indicated that female sex, lower baseline HIV-1 RNA levels, and optimal adherence were associated with virologic success, while a higher antiretroviral pill burden negatively impacted adherence.
[Primary isoniazid preventive therapy : A strategy still relevant in the era of test and treat ; literature review].
Rev Epidemiol Sante Publique
November 2022
Background: Tuberculosis remains a public health threat responsible as recently as 2018 for more than one million deaths. Chemoprophylaxis with isoniazid is one of the strategies implemented to control the disease. Although it is not yet widely prescribed, its utilization raises additional questions in the "test and treat" era of for anti-retroviral therapy.
View Article and Find Full Text PDFBackground: HIV-1 DNA persists in infected cells, forming viral reservoirs. Pre-antiretroviral treatment (ART) HIV-1 DNA load was reported to predict ART success in European severely immunocompromised patients. The aim of this study was to determine whether HIV-1 DNA levels are associated with virological success in less severely immunocompromised patients who receive early ART in sub-Saharan Africa.
View Article and Find Full Text PDF